Dare Bioscience, Inc. $DARE Shares Bought by AMH Equity Ltd

AMH Equity Ltd raised its stake in Dare Bioscience, Inc. (NASDAQ:DARE) by 17.8% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 193,603 shares of the biotechnology company’s stock after buying an additional 29,301 shares during the quarter. AMH Equity Ltd owned approximately 2.14% of Dare Bioscience worth $463,000 as of its most recent SEC filing.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on DARE. Wall Street Zen raised shares of Dare Bioscience to a “hold” rating in a report on Saturday, August 16th. Maxim Group raised shares of Dare Bioscience from a “hold” rating to a “buy” rating and set a $8.00 price objective on the stock in a report on Thursday, September 4th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dare Bioscience in a report on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Dare Bioscience currently has an average rating of “Hold” and a consensus price target of $10.00.

Dare Bioscience Trading Down 4.5%

Dare Bioscience stock opened at $1.93 on Friday. The stock has a market cap of $26.02 million, a price-to-earnings ratio of -0.90 and a beta of 1.14. The company’s 50-day moving average price is $2.10 and its two-hundred day moving average price is $2.49. Dare Bioscience, Inc. has a 52 week low of $1.83 and a 52 week high of $9.19.

Dare Bioscience (NASDAQ:DARE) last released its earnings results on Thursday, August 14th. The biotechnology company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.10. The company had revenue of ($0.02) million for the quarter, compared to analyst estimates of $0.14 million. Research analysts expect that Dare Bioscience, Inc. will post -0.49 earnings per share for the current fiscal year.

Dare Bioscience Company Profile

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.